Posted by Michael Wonder on 19 Mar 2026
Myriad Genetics receives FDA approval of the MyChoice CDx test as the companion diagnostic for Zejula (niraparib) for patients with ovarian cancer
17 March 2026 - Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States
Myriad Genetics today announced that the US FDA has approved the MyChoice CDx test as the companion diagnostic for Zejula (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer.
